Qiagen NV receives U.S. Clearance for QIAsymphony RGQ MDx system and diagnostic workflow for C. difficile


Monday, 5 May 2014 04:00pm EDT 

Qiagen NV:Says that its artus C. difficile QS-RGQ MDx Kit has been cleared by the U.S. Food and Drug Administration to qualitatively detect Clostridium difficile, a widespread healthcare-associated infection (HAI).In addition, the FDA has granted 510(k) regulatory clearance for the QIAsymphony RGQ MDx system, QIAGEN's flagship automation platform that is transforming laboratory workflows and driving dissemination of molecular diagnostics. 

Company Quote

22.84
-0.07 -0.31%
4:00pm EDT